Avalo Therapeutics
AVTX
43 hedge funds and large institutions have $88.5M invested in Avalo Therapeutics in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
16% more funds holding
Funds holding: 37 → 43 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 62.13% → 61.97% (-0.16%)
40% less capital invested
Capital invested by funds: $148M → $88.5M (-$59.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$27.5M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$1.57M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$360K |
| 4 |
Millennium Management
New York
|
+$254K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$106K |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
-$74K |
| 3 |
BlackRock
New York
|
-$63.5K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$60K |
| 5 |
Barclays
London,
United Kingdom
|
-$52.9K |
AVTX Hedge Fund Activity: Q1 2020 in Review
43 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2020, worth a combined $88.5M — down 40% from $148M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AVTX positions and 3 closed out — a net gain of 6 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Armistice Capital, adding an estimated $27.5M. The largest seller was Morgan Stanley, cutting an estimated $106K.
- 43 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2020, up from 37 in Q4 2019.
- Funds reported $88.5M of Avalo Therapeutics stock for Q1 2020, down 40% quarter-over-quarter.
- 9 funds opened new Avalo Therapeutics positions in Q1 2020 and 3 closed out, a net change of +6 holders.
- The largest Avalo Therapeutics buyer in Q1 2020 was Armistice Capital, an estimated $27.5M added.
- The largest Avalo Therapeutics seller in Q1 2020 was Morgan Stanley, an estimated $106K sold.
Based on aggregated 13F filings for Q1 2020.